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Abstract
Objective
To characterize the time course of ventricular volume expansion in genetic frontotemporal
dementia (FTD) and identify the onset time and rates of ventricular expansion in pre-
symptomatic FTD mutation carriers.
Methods
Participants included patients with a mutation in MAPT, PGRN, or C9orf72, or ﬁrst-degree
relatives of mutation carriers from the GENFI study with MRI scans at study baseline and at 1
year follow-up. Ventricular volumes were obtained from MRI scans using FreeSurfer, with
manual editing of segmentation and comparison to fully automated segmentation to establish
reliability. Linear mixed models were used to identify diﬀerences in ventricular volume and in
expansion rates as a function of time to expected disease onset between presymptomatic
carriers and noncarriers.
Results
A total of 123 participants met the inclusion criteria and were included in the analysis (18
symptomatic carriers, 46 presymptomatic mutation carriers, and 56 noncarriers). Ventricular
volume diﬀerences were observed 4 years prior to symptom disease onset for presymptomatic
carriers compared to noncarriers. Annualized rates of ventricular volume expansion were
greater in presymptomatic carriers relative to noncarriers. Importantly, time-intensive manually
edited and fully automated ventricular volume resulted in similar ﬁndings.
Conclusions
Ventricular volume diﬀerences are detectable in presymptomatic genetic FTD. Concordance of
results from time-intensive manual editing and fully automatic segmentation approaches
support its value as a measure of disease onset and progression in future studies in both
presymptomatic and symptomatic genetic FTD.
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Frontotemporal dementia (FTD) is a heritable neurodegen-
erative disorder characterized clinically by behavioral or lan-
guage deﬁcits and atrophy within the frontal and temporal
lobes. Approximately 30% of patients with FTD present with
an autosomal dominant family history, with mutations in
MAPT, PGRN, and C9Forf72 each presenting in 5%–25% of
familial FTD cases.1 Advances have been made in developing
disease-modifying treatments that target the underlying pa-
thology of FTD.2 As the initiation of FTD treatment is an-
ticipated to be necessary during the presymptomatic or
prodromal stages of the disease, biomarkers sensitive to these
disease periods are needed. Brain volumetric measurements
may be a promising candidate measure of disease onset and
progression, as atrophy in regions of the frontal and temporal
lobes may appear as early as 5–10 years before anticipated
disease onset in genetic FTD.3
Changes in ventricular volume represent a particularly at-
tractive candidate index of neuronal survival in FTD. Ven-
tricular expansion is seen across the heterogeneous clinical,
molecular, and genetic subtypes of FTD at the symptomatic
stage.4,5 Additional advantages include reduced image dis-
tortion from gradient nonlinearities due to the ventricles’
proximity to the magnet’s isocenter and high contrast in in-
tensity between ventricles and tissue, which facilitates auto-
mated segmentation techniques and implementation in large
clinical trials.6,7
Ventricular expansion during the presymptomatic stages of
genetic FTD has not yet been characterized. The objective of
the present study was to examine ventricular volume expan-
sion cross-sectionally and over a 1-year interval in carriers of
an FTD-causing genetic mutation and biologically related
noncarriers to determine its utility as a measure of early or
presymptomatic disease in genetic FTD.
Methods
Participants
The data used in this study were obtained from the multi-
center international Genetic Frontotemporal Dementia Ini-
tiative (GENFI). Participants were recruited from 12 research
sites across Canada, Sweden, Italy, the United Kingdom, and
the Netherlands and were either a known symptomatic carrier
of a pathogenic FTD-causing mutation in MAPT, PGRN, or
C9orf72 or a ﬁrst-degree relative of a known symptomatic
mutation carrier. As described previously,3 all participants
completed clinical interviews and standardized neuro-
psychological testing at baseline and at 1-year follow-up.
At-risk ﬁrst-degree relatives underwent genetic testing to
determine mutation carrier status.
Therefore, the sample was composed of symptomatic muta-
tion carriers and biologically related presymptomatic muta-
tion carriers and noncarriers.
Imaging and ventricular volume processing
Volumetric T1-weighted scans were acquired from a 3T
Philips (Best, the Netherlands), Siemens (Munich, Germany)
Trio, Siemens Skyra, or GE (Chicago, IL) machine; 1.5 Sie-
mens or GE scanners were utilized if a 3T was not available.
Scanning protocols were designed to accommodate the dif-
ferent scanners and ﬁeld strengths.4 Longitudinal scans col-
lected approximately 1 year after baseline, using the same
scanner and protocol as the baseline scan, were included in
the analysis.
The default longitudinal stream in FreeSurfer, version 5.1
(surfer.nmr.mgh.harvard.edu/), was used for ventricular vol-
ume processing.8 DICOM images were converted into NIfTI
format using the mri_convert command available in Free-
Surfer. An unbiased within-subject template was created using
inverse consistent registration.9 In addition, utilizing in-
formation from the within-subject template, processing steps
including skull stripping, Talairach transformation, atlas reg-
istration, spherical surface maps, and parcellations were ini-
tialized to increase reliability and statistical power.8
Ventricular segmentations of the lateral, inferior, third, and
fourth ventricles were visually checked and manually edited
by TPT, while blinded to familial mutation group member-
ship, mutation status (carrier vs noncarrier), and study period
(baseline or follow-up). Volumes of the left and right lateral
and inferior ventricles, third and fourth ventricles, and total
intracranial were extracted from aseg.txt longitudinal output
ﬁles.
Statistical analyses
Total ventricular volume was calculated as the sum of the left
and right lateral (including inferior), third, and fourth ven-
tricles and was expressed as a percentage of the individual’s
total intracranial volume. Main analyses compared ventricular
volume in presymptomatic carriers vs noncarriers, collapsed
across the mutation types to maximize sample size. Explor-
atory analysis included genetic mutation type (C9orf72,
PGRN, MAPT) to compare ventricular changes across the 3
genes.
Linear mixed models were used to examine diﬀerences in
baseline ventricular volumes and change over 1 year. Pre-
symptomatic carriers were compared to noncarriers to ex-
amine whether diﬀerences were detectable between
asymptomatic carriers vs noncarriers. Predictor variables in
these analyses included random eﬀects (family membership
[variance components covariance structure] and each
Glossary
FTD = frontotemporal dementia; GENFI = Genetic Frontotemporal Dementia Initiative; GS = genetic status.
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participant nested within the family [unstructured co-
variance structure], and a random intercept for each) and
ﬁxed eﬀects (visit [baseline, follow-up], genetic status [GS;
carrier, noncarriers], years from expected symptom onset,
and an interaction term for GS and years from expected
symptom onset). Years from expected age at symptom onset
were calculated by subtracting the mean age at symptom
onset within the family from the participant’s current age at
the time of baseline scan and follow-up scan.3 As ventricular
volume was predicted to change in a nonlinear fashion over
time as individuals approached the time of expected symp-
tom onset, a quadratic term for time from expected symp-
tom onset and its interaction with genetic mutation status
were included. Thus, using ventricular volume at time 1 and
2 within individuals, the model could evaluate whether
a linear or quadratic change in ventricular volume was
present across individuals as a function of years to expected
symptom onset. In order to create parsimonious models,
nonsigniﬁcant interaction terms were removed. The visit by
GS interaction was examined in a separate model without
the time to expected symptom onset by GS interaction due
to multicollinearity. Residual and inﬂuence analyses were
conducted to examine model quality and to identify po-
tential outliers. Studentized and conditional residuals were
examined, along with several inﬂuence diagnostic measures
including Cook D, COVRATIO, Restricted Likelihood
Distance, the PRESS statistic, and MDFFIT. Given
assumptions made in using the expected years to symptom
onset based on the average age at symptom onset in the
family, we also conducted a conﬁrmatory analysis using the
ﬁnal model, substituting years to expected symptom onset
with the participant’s age.
To examine diﬀerences in ventricular volume across the
presymptomatic, prodromal, and aﬀected stages of the dis-
ease, similar models were included to compare all mutation
carriers (symptomatic and presymptomatic mutation carriers
and progressors) relative to noncarriers. This model allows
ventricular volume to be examined across the continuum of
the disease and allowed an opportunity to examine whether
and how the model might change if symptomatic patients
were included with presymptomatic carriers, as has been done
in some prior studies.
Signiﬁcant interactions between years from expected
symptom onset and GS were followed up with t tests to
assess potential diﬀerences between the genetic carriers and
noncarriers in the years prior to and after expected symp-
tom onset, across the baseline and follow-up periods. Sig-
niﬁcant results were also followed up with analysis of
regional ventricular volumes (i.e., left and right). Given
reported gray matter asymmetries in PGRN mutation
carriers,10–12 we also computed and examined a laterality
index, deﬁned as the absolute diﬀerence between the left
and right ventricular volumes divided by the total ventric-
ular volume.3 All statistical analyses were conducted using
SAS (version 9.4).
Standard protocol approvals, registrations,
and patient consents
Local ethics committees at each site approved the study and all
participants provided written informed consent at enrollment.
Data availability
The data for this study were obtained from the GENFI data
freeze 2. Further details on the GENFI protocol, cohorts, and
data policies can be found at http://genﬁ.org.uk/. Due to the
sensitive nature of the genetic data in the GENFI cohort, and
consistent with practices adopted by the DIAN study of genetic
Alzheimer disease, individual data points are not presented to
preserve participant blinding to GS and conﬁdentiality. Sup-
plemental analysis as described below has been deposited in the
open data repository linked to this article (additional results,
e-tables 1–9, ﬁgure e-1, doi.org/10.5061/dryad.1qj7630).
Results
Participants
A total of 106 participants met the inclusion criteria. After
processing in FreeSurfer, 4 participants were removed prior to
statistical analysis: 1 due to scaling errors, 1 with extensive
segmentation errors, and 2 found to be extreme outliers
(1 carrier and 1 noncarrier from PGRN families; mean vol-
umes >3 SD), leaving 102 participants from 43 family cohorts
entered into the statistical model (table 1).
Table 1 Demographic characteristics of study
participants (n = 102)
Presymptomatic
carriers (n = 46)
Noncarriers
(n = 56)
Presymptomatic
carriers vs
noncarriers
Genotype p = 0.74
C9orf72 13 13
PGRN 29 36
MAPT 4 7
Sex p = 0.52
Female 25 34
Male 21 22
Years from
expected
symptom
onset at
baseline,
mean (SD)
−13.34 (12.65) −9.14 (15.60) p = 0.14
Age, y,
mean (SD)
44.66 (11.14) 50.56 (15.64) p = 0.03a
Years of
education,
mean (SD)
14.20 (3.47) 14.34 (3.51) p = 0.84
Group differences were assessed using χ2 tests and t tests.
a Significant at p < 0.05.
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Presymptomatic carriers vs noncarriers
The ﬁnal model included the GS by time to symptom onset
(linear) interaction, which illustrates diﬀerences between the
genetic groups at diﬀering points of time to symptom onset. A
diagnostic analysis identiﬁed 2 high-inﬂuential participants
(noncarriers) who were subsequently removed (table e-8, doi.
org/10.5061/dryad.1qj7630), resulting in a main eﬀect of GS
and a GS by time from symptom onset interaction. In addition,
visual inspection of the scatterplot indicated an extreme case
(noncarrier). Table 2 shows the model estimates, p values, and
conﬁdence intervals for the main eﬀects (visit, GS, time from
symptomonset [linear and quadratic term]), and the interaction
between time from symptom onset and GS. Unadjusted post
hoc t tests demonstrated diﬀerences in total ventricular volume
between presymptomatic carriers and noncarriers beginning 2
years prior to expected symptom onset, or beginning at 4 years
prior to expected symptom onset when one extreme case
(noncarrier) was removed from the model (ﬁgure 1). Table 3
shows the model estimates for the total ventricular volume and
total left and right volumes at speciﬁc years prior to expected
symptom onset (−25 years to 10 years). To create parsimonious
models, we excluded sites (n = 11) as random eﬀects and only
accounted for familymembership. In a conﬁrmatory analysis, we
included site as a random eﬀect in the ﬁnalmodel to examine the
potential inﬂuence of data collection from multiple sites. Con-
ﬁrmatory analysis supported that site was not signiﬁcant (p =
0.32). In the supportive analysis, with age used instead of
expected years to symptom onset, a signiﬁcant genetic group by
age interaction was found. Post hoc tests demonstrated that in
comparison to noncarriers, presymptomatic carriers showed
greater ventricular volume beginning at age 49.
Manually edited vs fully automated
ventricular volumes
Manual edits to the ventricular segmentations performed in
FreeSurfer were made on all study participants for each time
point (mean diﬀerences in edited vs unedited volumes are
reported in the e-supplement). Substitution of the fully au-
tomated ventricular volumes produced by FreeSurfer into the
ﬁnal models resulted in similar ﬁndings, demonstrating that
for presymptomatic carriers vs noncarriers, signiﬁcant diﬀer-
ences were observed at 4 years prior to symptom onset
(table e-9, a and b, doi.org/10.5061/dryad.1qj7630). See
table e-6 (doi.org/10.5061/dryad.1qj7630) for annualized
change of unedited ventricular volume.
Total ventricular expansion over 1 year
To assess potential diﬀerences in ventricular expansion over the
1-year interval, an additional model was comprised that included
the same family and participant random eﬀects as above and the
following ﬁxed eﬀects: visit, years to symptom onset (linear and
quadratic terms), GS, and an interaction between visit and GS.
Signiﬁcant visit by GS interaction was followed up by simple
eﬀects estimation. There was a signiﬁcant time byGS interaction
(p = 0.03); however, follow-up tests did not reach signiﬁcance
(all ps >0.18). Annual rates of change of total ventricular volume
are presented in table e-7 (doi.org/10.5061/dryad.1qj7630), as
a function of GS and years to expected symptom onset.
Mutation type
Given previously reported diﬀerences in atrophy patterns across
the diﬀerent genotypes, we conducted an exploratory analysis to
assess potential diﬀerences in total ventricular volume and in the
laterality index between the genotypes. Speciﬁcally, utilizing the
ﬁnal models from previous analysis (with the extreme case and 2
inﬂuential cases), we included genotype (C9orf72, PGRN,
MAPT) and the interaction between genotype and GS as ﬁxed
eﬀects in themodel. Therewas no signiﬁcant interaction between
genotype andGS (p= 0.10). There was no signiﬁcant interaction
between GS and genotype for the laterality index (p = 0.63).
Discussion
In this multicenter cohort of individuals from families with
genetic FTD, we found that ventricular volume enlargement
Table 2 Total ventricular volume estimates for
presymptomatic (n = 46) and noncarriers (n = 53),
with no influential cases (n = 2) or extreme case
(n = 1)
Estimate SE p Value 95% CI
Fixed effects
Intercept 0.38 0.34 0.27 −0.31, 1.07
Visit (baseline
and 1-year
follow-up;
ref = follow-up)
0.0004 0.01 0.97 −0.02, 0.02
Genetic statusa
(ref=noncarrier)
0.35 0.15 0.02b 0.05, 0.66
Time from
symptom onset
−0.02 0.01 0.07 −0.05, 0.002
Time from
symptom
onset2
0.0007 0.0002 0.0001b 0.0004, 0.001
Time from
symptom
onsetb genetic
status
0.02 0.007 0.02b 0.003, 0.03
Random effects
Family
membership
0.02 0.04 0.33
Participant 0.37 0.07 <0.0001b
Residual 0.004 0.0005 <0.0001b
Abbreviation: CI = confidence interval.
Time from symptom onset2 = quadratic term for time from symptom onset
variable. Ventricular volume is presented as a percentage of the partic-
ipant’s total intracranial volume. The interaction between time from symp-
tom onset and genetic status illustrates differences between the genetic
groups (presymptomatic carriers vs noncarriers) at differing points of time
to symptom onset.
a Genetic status (presymptomatic carrier vs noncarrier).
b Significant at p < 0.05.
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is detectable in the presymptomatic period, on average 4 years
prior to the anticipated onset of symptoms. We also provide
the ﬁrst estimates of annualized rates of ventricular expansion
in presymptomatic gene carriers compared to biologically
related noncarriers.
We also examined ventricular volume changes across the
presymptomatic and prodromal to symptomatic stages of the
disease, which oﬀers a unique opportunity to explore ven-
tricular volume changes throughout the disease continuum.
This method has also been employed by other studies3
delineating cross-sectional gray matter volumes in a genetic
cohort. When all mutation carriers (symptomatic and pre-
symptomatic) were included in the model, ventricular volume
changes emerged 12 years prior to symptom onset. This is in
contrast to the model including only presymptomatic par-
ticipants. Importantly, the presymptomatic model allows the
examination of subtle changes that emerge a few years prior to
disease symptom onset, unbiased by the increased rate of
change that may occur during the symptomatic period. Thus,
the diﬀerent model estimates and the earlier detection of
ventricular volume changes in the combined model of
Table 3 Total ventricle volume estimates from post hoc test between presymptomatic mutation carriers (n = 46) and
noncarriers (n = 53) by time to expected symptom onset with no influential cases (n = 2) or extreme case (n = 1)
225 y 220 y 215 y 210 y 25 y 0 y 5 y 10 y
Total ventricle
Estimate −0.10 −0.010 0.08 0.17 0.26 0.35 0.44 0.53
SE 0.16 0.14 0.13 0.13 0.14 0.15 0.18 0.20
p Value 0.54 0.94 0.53 0.18 0.05 0.02a 0.01a 0.01a
Total left ventricle
Estimate −0.07 −0.02 0.03 0.08 0.13 0.18 0.23 0.28
SE 0.08 0.07 0.06 0.06 0.06 0.07 0.08 0.10
p Value 0.39 0.80 0.60 0.18 0.05a 0.02a 0.01a 0.01a
Total right ventricle
Estimate −0.05 −0.01 0.03 0.07 0.11 0.15 0.19 0.23
SE 0.09 0.07 0.07 0.07 0.07 0.08 0.09 0.11
p Value 0.59 0.94 0.62 0.28 0.12 0.06 0.04a 0.03a
Ventricular volume is presented as a percentage of the participant’s total intracranial volume.
a Significant at p < 0.05.
Figure 1 Total ventricular volume by years from expected symptom onset in presymptomatic carriers vs noncarriers
Total ventricular volume by estimated years from expec-
ted symptom onset in presymptomatic carriers (blue, n =
46) and noncarriers (red, n = 53). Ventricular volume is
expressed as a percentage of intracranial volume. To
prevent disclosure of genetic status, individual data points
are not plotted. Differences are noted beginning at 4 years
prior to symptom onset as indicated by the dashed line
(p = 0.04).
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symptomatic patients with the presymptomatic individuals
likely reﬂects the increased the rate of change of ventricular
volume as the disease progresses. We suggest that the pre-
symptomatic carrier vs noncarrier model identifying mea-
surable diﬀerences 4 years prior to anticipated disease
symptom onset oﬀers the more accurate depiction of ven-
tricular volume changes throughout the presymptomatic
period.
Ventricular volume expansion has been well-documented in
patients with symptomatic sporadic and genetic forms of
FTD.13–15 The annual mean rates of expansion for symp-
tomatic mutation carriers in this GENFI cohort range from
6% to 11% and are in line with those reported in a series of 6
symptomatic C9orf72 carriers (mean annualized rate of ven-
tricular expansion of ;9%)14 and in 21 MAPT symptomatic
carriers (;9%).16 The expansion rate is slightly lower than
that reported previously in a cohort of patients with sporadic
FTD (mean 11%–14%)13 despite similarities in the mean age
of symptomatic participants. Prior small series of pre-
symptomatic mutation carriers have not detected signiﬁcant
diﬀerences in ventricular expansion rates in 7 C9orf72 pre-
symptomatic carriers (mean age 41) over a 6-month in-
terval,17 or in 9 presymptomatic MAPT carriers (1-year
interval).16
The varied and dramatic atrophy patterns observed in FTD
can introduce diﬃculties for automated segmentation pro-
grams.18 We focused our analysis on total ventricular volume
in particular, as in the presymptomatic state, the laterality
and exact brain regions that may display the earliest signs of
atrophy are not certain, even within a genetic mutation. Such
advantages of whole brain measurements, such as total
ventricular volume, for tracking outcomes have been
described.13,19,20 Despite theoretical concerns about lesser
sensitivity due to averaging across brain regions, this study
supports the potential for total ventricular volume meas-
urements to provide an unbiased approach to capture ac-
celerated rates of atrophy in presymptomatic and early
symptomatic stages of disease. Our comparison of time-
intensive, detailed manual editing of all scans included in the
study relative to the fully automated segmentation with no
editing produced remarkably similar results, further sup-
porting the feasibility of total ventricular volume as a prac-
tical measure of disease onset and progression in multicenter
clinical trials in FTD.
Despite the relatively large sample for a cohort of pre-
symptomatic FTD mutation carriers, subgrouping by muta-
tion type and years to expected symptom onset resulted in
signiﬁcant variability in some estimates. While signiﬁcant
variability in rates of atrophy has been reported within mu-
tation groups and even within families,21 in the current study,
the variability may potentially be due at least in part to the
sample size of subgroups. Due to subgroup sample size, the
examination of diﬀerences between carriers of C9orf72,
PRGN, and MAPT was exploratory, and did not reach
signiﬁcance. Examination of subregions of ventricular ex-
pansion identiﬁed the third ventricle as one of the earliest
markers in symptomatic patients (e-Results, doi.org/10.
5061/dryad.1qj7630). While we did not identify a signiﬁcant
interaction between GS and time to expected symptom onset
for the third ventricle in presymptomatic carriers, inspection
of the post hoc tests indicate early expansion of the third
ventricle (;14 years prior to expected symptom onset) in this
cohort as well. Together these ﬁndings suggest that enlarge-
ment of the third ventricle in presymptomaticC9orf72 carriers
may be one of the ﬁrst neuroimaging derived markers, due to
early thalamic atrophy.22
An additional potential limitation of this study is the use of the
estimated age at symptom onset, calculated by subtracting the
mean age at symptom onset within the family from the par-
ticipant’s age at the time of testing. While previous work has
demonstrated a strong association between patient age at
symptom onset and mean familial age at symptom onset,3 it
has been observed that age at symptom onset within families
is particularly variable in GRN mutations and somewhat var-
iable in C9ORF72. Although we found similar results when
current age or actual age at symptom onset was substituted
into the models, we cannot yet conﬁrm how accurately the
anticipated age at symptom onset represents the actual age in
the majority of individuals in the presymptomatic cohort.
Data anticipated from collaborations across large FTD
cohorts including LEFTDS, ARTFL, GENFI, and DINAD
examining individual age at symptom onset with family age at
symptom onset, parent age at symptom onset, and other
potential mediator factors will be helpful in the future to
improve such models. Furthermore, diﬀerences between the
presymptomatic carriers and noncarriers were based on
groupwise estimates and could not yet be applied on an in-
dividual basis. Data collection of additional longitudinal
timepoints continues for the GENFI cohort, which will in-
form future estimates of individual rates of change in ven-
tricular volumes.
Overall, the present study shows ventricular volume diﬀer-
ences during the presymptomatic period in genetic FTD
pathophysiology and supports the potential of application of
ventricular volume as one index of disease symptom onset in
the prodromal stages of FTD. Future longitudinal follow-up
of this GENFI cohort, as well as comparison with anticipated
results from other familial FTD cohorts such as Longitudinal
Evaluation of Familial Frontotemporal Dementia Subjects
(memory.ucsf.edu/leﬀtds), and with complementary meas-
ures such as rates of change in total brain volume will enable
further modeling according to speciﬁc genotype and conﬁrm
the rates of change.
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